See more : Aditya Birla Capital Limited (ABCAPITAL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of IntegraGen SA (ALINT.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IntegraGen SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Uttam Sugar Mills Limited (UTTAMSUGAR.BO) Income Statement Analysis – Financial Results
- freenet AG (FRTAF) Income Statement Analysis – Financial Results
- Eiken Chemical Co., Ltd. (4549.T) Income Statement Analysis – Financial Results
- China Chengtong Development Group Limited (0217.HK) Income Statement Analysis – Financial Results
- Woori Financial Group Inc. (316140.KS) Income Statement Analysis – Financial Results
IntegraGen SA (ALINT.PA)
About IntegraGen SA
IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.54M | 13.17M | 11.32M | 8.98M | 8.28M | 6.95M | 6.51M | 6.27M | 5.79M | 6.13M | 5.41M | 4.74M | 4.65M | 3.31M | 2.81M | 2.26M |
| Cost of Revenue | 7.52M | 13.17M | 11.28M | 9.07M | 2.56M | 4.55M | 5.25M | 4.84M | 4.71M | 4.92M | 5.55M | 4.62M | 4.72M | 2.01M | 3.73M | 3.65M |
| Gross Profit | 5.02M | -6.36K | 43.69K | -89.45K | 5.72M | 2.40M | 1.26M | 1.44M | 1.08M | 1.21M | -140.54K | 120.06K | -70.08K | 1.30M | -914.47K | -1.39M |
| Gross Profit Ratio | 40.03% | -0.05% | 0.39% | -1.00% | 69.03% | 34.49% | 19.39% | 22.91% | 18.67% | 19.70% | -2.60% | 2.53% | -1.51% | 39.20% | -32.51% | -61.31% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.98M | 0.00 | 0.00 |
| SG&A | 4.61M | 335.23K | 171.15K | 216.61K | 5.83M | 3.17M | 2.95M | 2.99M | 3.22M | 2.70M | 2.55M | 0.00 | 0.00 | 1.98M | 0.00 | 0.00 |
| Other Expenses | 525.46K | 231.77K | 97.90K | 133.73K | -87.30K | -1.35K | -53.06K | 444.74K | 0.00 | 0.00 | -31.42K | -23.16K | -163.85K | -226.91K | -629.54K | -611.66K |
| Operating Expenses | 5.14M | 103.46K | 73.25K | 82.88K | 6.22M | 3.73M | 2.53M | 3.42M | 2.99M | 2.77M | 2.82M | 2.51M | 2.33M | 4.11M | 1.92M | 1.26M |
| Cost & Expenses | 12.66M | 13.28M | 11.35M | 9.15M | 8.78M | 8.29M | 7.78M | 8.26M | 7.70M | 7.69M | 8.38M | 7.13M | 7.05M | 6.12M | 5.65M | 4.91M |
| Interest Income | 64.12K | 9.26K | 1.97K | 3.44K | 61.00K | 2.43K | 71.62K | 62.32K | 52.29K | 52.11K | 79.23K | 67.14K | 71.51K | 30.43K | 0.00 | 21.53K |
| Interest Expense | 8.37K | 11.92K | 4.89K | 5.21K | 2.65K | 105.00 | 0.00 | 15.00 | 119.00 | 50.00 | 7.00 | 0.00 | 229.00 | 4.09K | 6.25K | 519.67K |
| Depreciation & Amortization | 198.21K | 201.56K | 205.89K | 226.34K | 256.10K | 135.90K | 123.30K | 105.63K | 88.42K | 80.36K | 80.36K | 40.88K | -152.28K | 33.28K | 22.34K | -207.73K |
| EBITDA | -52.50K | 69.96K | 96.45K | -235.89K | -179.20K | -1.20M | -1.81M | -1.67M | -1.45M | -1.61M | -2.80M | -2.31M | -2.46M | -3.48M | -3.28M | -3.21M |
| EBITDA Ratio | -0.42% | 0.70% | 1.56% | 0.60% | -0.85% | -15.01% | -27.76% | -26.67% | -38.44% | -26.19% | -51.96% | -48.26% | -53.94% | -89.76% | -118.38% | -140.63% |
| Operating Income | -183.77K | -109.82K | -29.55K | -172.33K | -363.00K | -1.18M | -1.93M | -1.78M | -2.31M | -1.69M | -2.89M | -2.37M | -2.40M | -2.81M | -2.84M | -2.65M |
| Operating Income Ratio | -1.47% | -0.83% | -0.26% | -1.92% | -4.38% | -16.97% | -29.65% | -28.36% | -39.97% | -27.51% | -53.45% | -49.94% | -51.66% | -84.83% | -100.83% | -117.08% |
| Total Other Income/Expenses | -75.31K | -4.39K | -70.79K | -213.31K | -74.88K | -153.30K | 734.66K | -142.58K | 779.81K | 178.79K | 9.76K | 54.59K | -86.80K | -705.10K | -496.18K | -1.09M |
| Income Before Tax | -259.08K | -143.52K | -114.32K | -467.45K | -438.00K | -1.33M | -1.20M | -1.92M | -1.86M | -1.51M | -2.88M | -2.31M | -2.49M | -3.51M | -3.41M | -3.73M |
| Income Before Tax Ratio | -2.07% | -1.09% | -1.01% | -5.21% | -5.29% | -19.17% | -18.37% | -30.63% | -32.14% | -24.59% | -53.27% | -48.79% | -53.53% | -106.13% | -121.09% | -165.12% |
| Income Tax Expense | -87.68K | -140.01K | -129.73K | -92.43K | 153.00K | 192.86K | 333.30K | 270.62K | 326.41K | 463.60K | 337.61K | -586.98K | -448.60K | -616.54K | -599.06K | -53.05K |
| Net Income | -171.40K | -3.51K | 15.41K | -375.02K | -285.00K | -1.14M | -862.17K | -1.65M | -1.53M | -1.04M | -2.55M | -1.73M | -2.04M | -2.90M | -2.73M | -3.03M |
| Net Income Ratio | -1.37% | -0.03% | 0.14% | -4.18% | -3.44% | -16.40% | -13.25% | -26.32% | -26.50% | -17.03% | -47.03% | -36.41% | -43.88% | -87.51% | -97.18% | -133.90% |
| EPS | -0.03 | 0.00 | 0.00 | -0.06 | -0.04 | -0.18 | -0.13 | -0.33 | -0.31 | -0.21 | -0.62 | -0.42 | -0.54 | -0.77 | -0.92 | -1.02 |
| EPS Diluted | -0.03 | 0.00 | 0.00 | -0.06 | -0.04 | -0.18 | -0.13 | -0.33 | -0.30 | -0.21 | -0.61 | -0.42 | -0.54 | -0.77 | -0.92 | -1.02 |
| Weighted Avg Shares Out | 6.61M | 6.63M | 6.62M | 6.65M | 6.49M | 6.46M | 6.48M | 5.02M | 5.03M | 4.94M | 4.12M | 4.12M | 3.77M | 3.77M | 2.97M | 2.97M |
| Weighted Avg Shares Out (Dil) | 6.61M | 6.63M | 6.62M | 6.65M | 6.49M | 6.46M | 6.48M | 5.02M | 5.11M | 4.97M | 4.17M | 4.12M | 3.77M | 3.77M | 2.97M | 2.97M |
Source: https://incomestatements.info
Category: Stock Reports